LuciTala

LuciTala uses and dosage

LuciTala (Talazoparib), generic Talzenna is a prescription medicine used to treat adult patients with deleterious or suspected deleterious BRCA-mutated (gBRCAm) HER2-negative advanced or metastatic breast cancer. It is a single agent. Talazoparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. Talazoparib in combination with Enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). LuciTala manufactured by Lucius Pharma Ltd. in Laos. Recommended Dosage for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer: • The recommended dosage of Talazoparib is 1 mg taken orally once daily with or without food until disease progression or unacceptable toxicity. • For adverse reactions, dosing interruption or dose reduction should be considered. Recommended Dosage for HRR Gene-mutated mCRPC: • The recommended

LuciTala side effects

The most common adverse reactions of Talazoparib are: Blood cell disorders, Tiredness, High blood sugar, Changes in liver function tests, Low calcium levels, also called hypocalcemia, Nausea and vomiting, Headache, Hair loss, Diarrhea, Loss of appetite.

Originator brand

Talzenna by Pfizer

Made by

Lucius Pharma

This information is provided for reference only and is not medical advice. Always consult a qualified healthcare professional.